journal article·2026-01-12Open access

Engineering Complex Breast Tumor-Stroma Models: TMPyP4-Photodynamic Therapy Is More Effective at the Metastatic Site in Breast Tumors

Salma T. Rafik, Jasmine Ho, Alexander J. MacRobert, Umber Cheema

Abstract

The breast tumor microenvironment encompasses distinct biophysical, biochemical, and cellular aspects, including a dense extracellular matrix and an array of tumor and stromal cells. The dynamics between tumor cells and their microenvironment can alter tumor behavior and impact treatment responses. Herein, tumor-stroma models (tumoroids) were engineered using dense collagen l to spatially compartmentalize a breast tumor mass in either its primary site (breast) or metastatic site (lung) to test the efficacy of photodynamic therapy (PDT) using a photosensitizer (TMPyP4) as a single treatment and in combination with doxorubicin. For tumoroids with a primary stroma, PDT efficacy was comparable for both MCF-7 and MDA-MB-231. In contrast, MCF-7 tumoroids with a metastatic stroma exhibited a greater treatment response with a 7.2-fold decrease in viability compared to the MCF-7 tumoroids with a primary stroma, whereas only a 1.1-fold decrease was seen for the MDA-MB-231 models. For MDA-MB-231 tumoroids with a primary stroma, combination treatment with PDT and doxorubicin gave the best outcomes. The viability data in the 3D models correlated with noninvasive imaging of hypoxia gradients, where hypoxia became progressively alleviated with increasing treatment efficacy. ln summary, these results highlight the necessity to model the tumor stroma as this can directly impact drug efficacy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Photodynamic Therapy Research Studies · Nanoplatforms for cancer theranostics · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

UCL Centre for 3D Models of Health and Disease, UCL Division of Surgery and Interventional Science, Faculty of Medical Sciences, Charles Bell House, 43-45 Foley Street

University College London

Department of Clinical Pharmacology, Faculty of Medicine

Alexandria University

Funding

Egyptian Cultural and Educational Bureau · Engineering and Physical Sciences Research Council · Medical Research Council · Ministry of Higher Education and Scientific Research · Rosetrees Trust

References (87)

Show source-provided references
1. 10.3322/caac.2183410.3322/caac.21834 ↗
2. 10.1016/j.gendis.2018.05.00110.1016/j.gendis.2018.05.001 ↗
3. 10.3389/fimmu.2020.59853210.3389/fimmu.2020.598532 ↗
4. 10.1186/s40001-024-01711-z10.1186/s40001-024-01711-z ↗
5. 10.1016/j.semcancer.2019.07.02810.1016/j.semcancer.2019.07.028 ↗
7. 10.1038/3502109310.1038/35021093 ↗
8. 10.1016/j.molcel.2015.10.03110.1016/j.molcel.2015.10.031 ↗
9. 10.1200/JCO.2012.43.413410.1200/JCO.2012.43.4134 ↗
10. 10.1097/MD.000000000000461410.1097/MD.0000000000004614 ↗
11. 10.1186/bcr263510.1186/bcr2635 ↗
12. 10.1371/journal.pone.016866910.1371/journal.pone.0168669 ↗
13. 10.1158/1078-0432.CCR-04-242110.1158/1078-0432.CCR-04-2421 ↗
14. 10.3390/cancers1317428710.3390/cancers13174287 ↗
15. 10.3389/fonc.2023.117026410.3389/fonc.2023.1170264 ↗
16. 10.1038/nrc107110.1038/nrc1071 ↗
17. 10.3390/jcm902048310.3390/jcm9020483 ↗
18. 10.1245/aso.2004.03.025/jcm902048310.1245/aso.2004.03.025/jcm9020483 ↗
19. 10.1002/ijc.140010.1002/ijc.1400 ↗
20. Rosado-Galindo H. · 2021
21. 10.3389/fbioe.2021.66050210.3389/fbioe.2021.660502 ↗
22. 10.1038/srep4404510.1038/srep44045 ↗
23. 10.1038/s41416-020-0973-910.1038/s41416-020-0973-9 ↗
24. Ho, J. Dynamic hypoxic pre-conditioning of cells seeded in tissue-engineered scaffold to improve neovascularisation; UCL (University College London): london, 2023https://discovery.ucl.ac.uk/id/eprint/10173071.
25. 10.1016/j.dyepig.2017.03.02610.1016/j.dyepig.2017.03.026 ↗
26. 10.1016/j.actbio.2018.09.04110.1016/j.actbio.2018.09.041 ↗
27. 10.1016/j.mattod.2022.07.00610.1016/j.mattod.2022.07.006 ↗
28. 10.1142/S108842461950011110.1142/S1088424619500111 ↗
29. 10.1016/0304-3835(93)90188-F10.1016/0304-3835(93)90188-F ↗
30. 10.3390/pharmaceutics1504119410.3390/pharmaceutics15041194 ↗
31. 10.1562/2005-05-30-RA-55310.1562/2005-05-30-RA-553 ↗
32. 10.1038/s41419-024-07215-210.1038/s41419-024-07215-2 ↗
33. 10.3390/ijms2011267010.3390/ijms20112670 ↗
34. 10.1016/j.biopha.2018.07.04910.1016/j.biopha.2018.07.049 ↗
35. Krammer B. · Anticancer Res. · 2001 · 21 · 4271
36. 10.1186/s12935-016-0348-810.1186/s12935-016-0348-8 ↗
37. 10.1023/A:100598660601010.1023/A:1005986606010 ↗
38. 10.1021/acs.jpclett.5b0173910.1021/acs.jpclett.5b01739 ↗
39. 10.1021/acs.molpharmaceut.4c0033310.1021/acs.molpharmaceut.4c00333 ↗
40. 10.1016/j.celbio.2024.10000110.1016/j.celbio.2024.100001 ↗
41. 10.1039/D1SC04656J10.1039/D1SC04656J ↗
42. 10.1038/s41565-021-00858-810.1038/s41565-021-00858-8 ↗
43. 10.3390/pharmaceutics1503102610.3390/pharmaceutics15031026 ↗
44. 10.1016/j.jphotobiol.2021.11225810.1016/j.jphotobiol.2021.112258 ↗
45. 10.1016/j.apmt.2021.10101010.1016/j.apmt.2021.101010 ↗
46. 10.1016/S0248-4900(01)01118-210.1016/S0248-4900(01)01118-2 ↗
47. 10.1038/sj.bjc.669052610.1038/sj.bjc.6690526 ↗
48. Kim M.-Y. · Cancer Res. · 2003 · 63 · 3247
49. 10.1016/j.jphotobiol.2014.12.00310.1016/j.jphotobiol.2014.12.003 ↗
50. 10.3389/fbioe.2022.83769310.3389/fbioe.2022.837693 ↗
51. 10.3390/ijms22231261810.3390/ijms222312618 ↗
52. 10.1038/s41598-018-21075-910.1038/s41598-018-21075-9 ↗
53. 10.1007/s10103-024-04141-910.1007/s10103-024-04141-9 ↗
54. 10.1002/cbdv.20240278210.1002/cbdv.202402782 ↗
55. 10.3390/ph1705057610.3390/ph17050576 ↗
56. 10.3390/cancers902001810.3390/cancers9020018 ↗
57. 10.1111/j.1751-1097.2007.00248.x10.1111/j.1751-1097.2007.00248.x ↗
58. 10.1016/j.bbamcr.2010.10.01710.1016/j.bbamcr.2010.10.017 ↗
59. 10.1038/sj.cdd.440044610.1038/sj.cdd.4400446 ↗
60. 10.1186/s12935-019-0815-010.1186/s12935-019-0815-0 ↗
61. 10.1016/j.drudis.2021.09.02010.1016/j.drudis.2021.09.020 ↗
62. 10.1016/j.jphotobiol.2017.04.03710.1016/j.jphotobiol.2017.04.037 ↗
63. 10.1002/adhm.20220174910.1002/adhm.202201749 ↗
64. 10.1158/0008-5472.CAN-12-223310.1158/0008-5472.CAN-12-2233 ↗
65. 10.1038/s41388-022-02258-110.1038/s41388-022-02258-1 ↗
66. 10.1016/S1044-579X(02)00023-810.1016/S1044-579X(02)00023-8 ↗
67. 10.1016/j.yexcr.2014.05.01210.1016/j.yexcr.2014.05.012 ↗
68. 10.1007/s10456-014-9439-010.1007/s10456-014-9439-0 ↗
69. 10.1038/s41598-023-45832-710.1038/s41598-023-45832-7 ↗
70. 10.1186/s13058-018-1013-z10.1186/s13058-018-1013-z ↗
71. 10.1039/D4BM01569J10.1039/D4BM01569J ↗
72. 10.1016/j.biomaterials.2020.11985310.1016/j.biomaterials.2020.119853 ↗
73. 10.1002/adtp.20190012110.1002/adtp.201900121 ↗
74. 10.1088/1758-5090/ae0a8210.1088/1758-5090/ae0a82 ↗
75. 10.1021/acsabm.0c0044810.1021/acsabm.0c00448 ↗
76. 10.3892/mmr.2020.1152910.3892/mmr.2020.11529 ↗
77. 10.1038/onc.2009.29910.1038/onc.2009.299 ↗
78. 10.1016/j.cell.2004.06.00610.1016/j.cell.2004.06.006 ↗
79. 10.1016/j.celrep.2019.09.00410.1016/j.celrep.2019.09.004 ↗
80. 10.1016/j.actbio.2019.02.01510.1016/j.actbio.2019.02.015 ↗
81. 10.1016/j.apmt.2023.10199410.1016/j.apmt.2023.101994 ↗
82. 10.1111/php.1333910.1111/php.13339 ↗
83. 10.3389/fbioe.2020.0104010.3389/fbioe.2020.01040 ↗
84. 10.1073/pnas.140665511110.1073/pnas.1406655111 ↗
85. 10.1186/s12885-023-11674-910.1186/s12885-023-11674-9 ↗
86. 10.1038/nature1016910.1038/nature10169 ↗
87. 10.1084/jem.2013191610.1084/jem.20131916 ↗